comparemela.com

Latest Breaking News On - Georgea samuel - Page 1 : comparemela.com

Lineage Cell Therapeutics : Opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT .

State of californiaUnited statesSan diegoSheppard mullin richter hamptonGeorgea samuelCompany current report on formRegistration statement the base prospectusSecurities exchangeCompany registration statement on formB riley securities incCommon shares the companyExchange commissionLineage cell therapeutics incCommission file numberExchange commission theRichter hampton

Lineage Cell Therapeutics : Immediate Report -March 24, 2024 at 04:37 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT .

New yorkUnited statesCity of new yorkGeorgea samuelSubsidiary of the companyCommission file numberLineage cell therapeutics incExchange commission theGovernmental authorityB riley securities incCantor fitzgerald coCompany the prospectusExchange commissionWarranties of the companyPlacement shares of the companyCompany or lineage

Lineage Cell Therapeutics : FORM S-3-Registration Statements -March 10, 2024 at 04:43 am EDT

As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. 333- UNITED STATES SECURITIES.

United statesState of californiaTel avivGeorgea samuelBrianm culleyExchange commissionRoche groupRoche ltdLineage cell therapeutics incGenentech incImplications of beinga smaller reporting companyExchange commission onCalifornia institute for regenerative medicineTel aviv stock exchangeEterna therapeutics incSecurities exchange

Lineage Cell Therapeutics : Results of Annual Meeting was held on September 6, 2023 -Today at 03:01 am

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT .

United statesGeorgea samuelBrianm culleyAngusc russellDon baileyNealc bradsherDipti aminAnula jayasuriyaMichaelh mulroyDeborah andrewsAlfredd kingsleyLineage cell therapeutics incSecurities exchangeExchange commission onMeeting of lineage cell therapeutics incSecurities exchange act

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides B

Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 MillionRetinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Rel.

United statesMike biegaKevinl cookBrianm culleyDipti aminAnula jayasuriyaGeorgea samuelCell therapeutics incHadasit medical research servicesDevelopment ltd hadasitExchange commissionLineage cell therapeutics incIsrael innovation authorityCompany on twitter lineagecellRoche groupPaycheck protection program

vimarsana © 2020. All Rights Reserved.